Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers
Authors:
- 22 December 2009
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 29 (3) , 259-267
Abstract
With the emergence of multiple meningococcal serogroups in different geographic areas, broad vaccine protection from infancy is desirable. One hundred and seventy-five infants received either two doses of a meningococcal quadrivalent (A, C, W-135, Y) conjugate vaccine (MenACWY-CRM) at 6 and 12 months, one dose of MenACWY-CRM at 12 months, or MenC at 12 months and MenACWY-CRM at 18 months. Bactericidal antibody titers using human complement were measured before and 1 month after each dose. Injection-site reactions were reported by 22–45% of participants following MenACWY-CRM given at 6 or 12 months. Similar proportions of subjects had injection-site reactions following two doses of MenACWY-CRM (32–41%) or one dose of MenC (26–44%). The incidence of systemic adverse events was comparable between groups. After two doses of MenACWY-CRM, the percentages of participants reporting hSBA titers ≥8 were 100% for C, W-135, and Y, and 84% for A. Serogroup C titers were more than 10-fold higher after two doses of MenACWY-CRM than after one dose of MenC or MenACWY-CRM at 12 months. Serogroup C titers were comparable following a single dose of MenACWY-CRM or MenC at 12 months. MenACWY-CRM is well tolerated and immunogenic given at 12 months, or two doses at 6 and 12 months of age.Keywords
This publication has 17 references indexed in Scilit:
- Immunogenicity and Immune Memory of a Nonadjuvanted Quadrivalent Meningococcal Glycoconjugate Vaccine in InfantsThe Pediatric Infectious Disease Journal, 2009
- Demonstration of Immunologic Memory Using Serogroup C Meningococcal Glycoconjugate VaccineThe Pediatric Infectious Disease Journal, 2009
- Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in InfantsJAMA, 2008
- Use of Meningococcal Vaccines in the United StatesThe Pediatric Infectious Disease Journal, 2007
- Antibody Persistence 3 Years after Immunization of Adolescents with Quadrivalent Meningococcal Conjugate VaccineThe Journal of Infectious Diseases, 2006
- Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in SpainVaccine, 2005
- Meningococcal polysaccharide–protein conjugate vaccinesThe Lancet Infectious Diseases, 2005
- Induction of Immunologic Memory by Conjugated vs Plain Meningococcal C Polysaccharide Vaccine in ToddlersJAMA, 1998
- Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants.Journal of Clinical Investigation, 1975
- HUMAN IMMUNITY TO THE MENINGOCOCCUSJournal of Experimental Medicine, 1969